continues

Sanofi continues to ship sturdy enterprise EPS(1) development pushed by greater gross sales and improved margins in Q1  Paris, April 28, 2022 Q1 2022 gross sales development of 8.6% at CER pushed by Dupixent® and CHC Specialty Care grew 17.8% pushed by Dupixent® (€1,614 million, +45.7%) Vaccines have been up […]